scholarly journals S1913 Antibiotic Combination Therapy Improves Symptoms of Parkinson’s Disease in Individuals With Chronic Constipation

2021 ◽  
Vol 116 (1) ◽  
pp. S840-S840
Author(s):  
Rhys Collyer ◽  
Anoja W. Gunaratne ◽  
Annabel K. Clancy ◽  
Thomas J. Borody
2018 ◽  
Vol 10 (4) ◽  
pp. 65-71
Author(s):  
Yu. N. Bykov ◽  
T. B. Bender ◽  
Yu. N. Vasiliev ◽  
A. N. Kalyagin ◽  
Т. М. Maksikova ◽  
...  

Motor and non-motor symptoms are identified in the clinical picture of Parkinson's disease (PD). Among its non-motor manifestations, cognitive impairment (CI) and emotional disorders play a special role in PD. It is important to search for new forms and methods of cognitive therapy in patients with PD.Objective:to analyze neuropsychological status and quality of life (QOL) in PD patients and to evaluate the efficiency of personalized combination therapy with a stimulating cognitive motor training on computer and mobile devices in these patients.Patients and methods. The investigation enrolled 112 patients with PD. A study group included 56 PD patients who received a cycle of combination therapy with cognitive-motor training on PC and mobile devices; a control group consisted of 56 PD patients who had only a drug therapy cycle. To evaluate neuropsychological status and QOL, the investigators used the Montreal Cognitive Assessment (MoCA), the McNair and Kahn memory self-evaluation scale, the Hospital Anxiety and Depression Scale (HADS), and the 36-Item Short Form Health Survey (SF-36) questionnaire.Results and discussion. According to MoCA scores, CI of varying severity was diagnosed in the majority of patients: in 75 and 80.4% in the study and control groups, respectively. Depressive syndrome was detected in 53.6 and 64.3% in these groups, respectively. According to the SF-36, the physical status of patients had the greatest effect in reducing their QOL. There were treatment-induced statistically significant positive changes for the following domains: physical functioning (p<0.01), role-physical functioning (p<0.001), pain intensity (p<0.01), general health (p<0.01), role emotional (p<0.0001), and mental health (p<0.01).Conclusion.The investigation has shown the efficiency of personalized therapy including stimulating cognitive-motor training on computer and mobile devices, which improves neuropsychological status and QOL in patients with PD.


2018 ◽  
Vol 19 (9) ◽  
pp. 937-945 ◽  
Author(s):  
Dirk Woitalla ◽  
Antoine Dunac ◽  
Ali Safavi ◽  
Maria-Gabriella Ceravolo ◽  
Juan Carlos Gomez Esteban ◽  
...  

Neurology ◽  
1996 ◽  
Vol 47 (Issue 6, Supplement 3) ◽  
pp. 200S-209S ◽  
Author(s):  
V. V. Myllyla ◽  
K. Sotaniemi ◽  
O. Maki-Ikola ◽  
U. K. Rinne ◽  
E. H. Heinonen

1996 ◽  
Vol 24 (3) ◽  
pp. 271-277 ◽  
Author(s):  
N Ogawa ◽  
M Asanvma ◽  
K Tanaka ◽  
K Matsuura ◽  
K Iida ◽  
...  

Bromocriptine, a dopamine agonist, alleviates symptoms of Parkinson's disease, even when administered alone, and is used for its treatment. Better therapeutic effects are, however, achieved when bromocriptine is used in combination with levodopa. In this study, we examined the biochemical changes caused by bromocriptine administration with and without levodopa, and evaluated the effects of the treatments on dopamine turnover in the mouse striatum. Results show that dopamine turnover is suppressed by the administration of bromocriptine alone with a slight decrease in the amount of dopamine, and dopamine turnover is very strongly promoted by the administration of levodopa. When the two drugs are administered together, bromocriptine enhances the levodopa-induced increase in dopamine turnover in the striatum. These findings indicate that bromocriptine therapy in combination with levodopa enhances the dopaminergic function and suggest that the combination therapy of bromocriptine and levodopa shows good efficacy. The results of this study may, thus, provide a theoretical basis for the combination therapy of bromocriptine and levodopa.


Sign in / Sign up

Export Citation Format

Share Document